Representatives from two Japanese businesses, KIZUNA KAIHATSU and WELL MEDICAL GROUP, met with the United Republic of Tanzania’s Embassy in Tokyo. Mr. Willy Ngoya of WILNA International, a member of the Tanzanian Diaspora in Japan, presented the businesses. The team stated that the purpose of their visit was to investigate possible business partnerships and Official Development Assistance (ODA) initiatives in Tanzania. Along with other business representatives, Mr. Tetsuo Maeda, Director and Chief Sales Executive of Well Medical Group and Mr. Seichi Ryoke, Chief Executive Officer of Kizuna Kaihatsu, attended.

In light of the recently signed Memorandum of Cooperation (MOC) between Tanzania and Japan on the Carbon Credit Mechanism, the Embassy stated that the proposal is in line with Tanzania’s environmental and green energy commitments and promised to facilitate collaboration with pertinent government institutions, including the Vice President’s Office. The Embassy noted that by promoting sustainable waste management and carbon reduction, the project might enhance current bilateral cooperation under this structure.

Mr. Maeda of Well Medical Group gave a presentation on the company’s anti-aging and regenerative medicine initiatives. He described the company’s business connections in Hanoi and Ho Chi Minh City, Vietnam, as well as its clinics in Tokyo, Osaka, and Kobe. Using patients’ own cells, the clinics offer stem cell therapy aimed at regenerative medicine, diabetes control, anti-aging and general health enhancement. Fat cells are extracted, cultivated into billions of cells and then returned into patients with minimally invasive procedures that leave no surgical scars. The plan for Tanzania is on setting up clinics and labs in Zanzibar, with the possibility of future growth for medical tourism aimed at European tourists. As part of the project, Tanzanian medical staff will receive professional training in regenerative medicine, which could lead to a wider deployment throughout Africa.

The Embassy offered to put the businesses in touch with the appropriate Tanzanian authorities and reaffirmed its support. Submitting supporting documentation to the Embassy, organizing site visits to Kizuna Kaihatsu’s production facilities and Well Medical Group’s demonstration clinics and maintaining contact with Tanzanian authorities for ODA approval and partnership facilitation are the next steps that have been decided upon. There will be follow-up meetings to discuss project specifics and implementation schedules in more depth.

Additionally, the Embassy thanked both businesses for their creative ideas, which have great potential to support Tanzania’s improved medical services and environmental sustainability. The Embassy also expressed its profound gratitude to Mr. Willy Ngoya for his ongoing efforts to foster investment cooperation between Japan and Tanzania and to connect the Embassy with Japanese businesses.

One of India’s top providers of specialized cancer treatments, Healthcare Global Enterprises Limited (HCG), has declared its intention to increase its market share in Africa. An investment of up to Rs. 700 lakhs (about $840,000) in Cancer Care Kenya Limited, a step-down subsidiary of HCG, has been approved by the company’s Board of Directors.

The investment will be made in equity shares of Cancer Care Kenya Limited, subject to relevant regulatory approvals and the fulfillment of certain procedures. Based on the fair worth of Cancer Care Kenya’s shares as established by an independent valuation expert, the decision was made at the Board meeting on November 12, 2023.

This action seems to be a component of HCG’s plan to increase its market share in the African healthcare industry. Located in Nairobi, Kenya, Cancer Care Kenya Limited offers radiation and chemotherapy therapies along with a 15-bed daycare center.

HCG’s trust in the African healthcare market’s potential for growth, especially in oncologist treatments, may be demonstrated by this investment. It also demonstrates the company’s dedication to diversifying its sources of income and growing its global footprint.

The Securities and Exchange Board of India (SEBI) and other relevant regulations are followed in the structuring of the investment. HCG has indicated that it complies with cross-border investment standards by stating that the proposed investment is dependent upon the required regulatory clearances.

Apart from its investment in Cancer Care Kenya, Healthcare Global Enterprises has presented a thorough multi-year expansion plan. The strategy’s main objectives include oncology expansion, clinical excellence, deepening regional networks, improving margins, precision oncology and digital health platforms.

This multifaceted strategy shows HCG’s dedication to long-term expansion and its goal to solidify its standing as a pioneer in oncology services in India and around the world.

Together with its all-encompassing growth strategy, Healthcare Global Enterprises’ investment in Cancer Care Kenya may improve its standing in the expanding African healthcare market and support its long-term expansion in specialized oncology services.